Intra-Cellular Therapies Inc (ITCI)
89.24
+3.07
(+3.56%)
USD |
NASDAQ |
Nov 05, 16:00
89.31
+0.07
(+0.08%)
After-Hours: 20:00
Intra-Cellular Therapies Research and Development Expense (Annual): 180.14M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 180.14M |
| December 31, 2022 | 134.72M |
| December 31, 2021 | 88.84M |
| December 31, 2020 | 65.78M |
| December 31, 2019 | 89.12M |
| December 31, 2018 | 132.17M |
| Date | Value |
|---|---|
| December 31, 2017 | 79.42M |
| December 31, 2016 | 93.83M |
| December 31, 2015 | 87.72M |
| December 31, 2014 | 21.23M |
| December 31, 2013 | 23.03M |
| December 31, 2012 | 15.49M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
65.78M
Minimum
2020
180.14M
Maximum
2023
111.72M
Average
89.12M
Median
2019
Research and Development Expense (Annual) Benchmarks
| ACADIA Pharmaceuticals Inc | 351.62M |
| Ionis Pharmaceuticals Inc | 899.62M |
| Madrigal Pharmaceuticals Inc | 272.35M |
| AbbVie Inc | 8.453B |
| Arcus Biosciences Inc | 340.00M |